The Chromosome 22q11 Deletion Syndrome (22q11DS or 22q11 Syndrome) is the most common inherited chromosomal deletion syndrome, affecting approximately 1/4000 births. The 22q11 Thymus Project is a multi-institutional, multidisciplinary collaboration, which has the overarching goal of understanding the molecular and cellular pathogenesis of thymic abnormalities in 22q11 Syndrome to develop cell-based therapies to regenerate the thymus and restore thymic function in affected patients. Additionally, the 22q11 Syndrome is an experiment of nature that permits a deeper understanding of normal human thymic organogenesis and thymopoiesis.

For more information on the 22q11 Deletion Syndrome Consortium, click here.

Please Contact Us for information regarding ongoing and future programs.